Metraipolis › archive › dc_2fed950fe801

Evaluating the Beneficial Effect of Empagliflozin in Reducing Hospitalisation for Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review — Europe PMC PMID:41235287

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41235287
DOI: 10.7759/cureus.96593
License (as archived): solo-consultazione
Archived: 2026-11-08T16:12:53.339Z
SHA-256 of the archived text: 1ebb5d6ccb855ab6860013eec9d0f92fc34a119dcfc44dd0bcd0682ce5946c17
Stable URL of this page: https://metraipolis.com/documento/dc_2fed950fe801

How to cite

Evaluating the Beneficial Effect of Empagliflozin in Reducing Hospitalisation for Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review — Europe PMC PMID:41235287 — Europe PMC (en), https://europepmc.org/article/MED/41235287 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2fed950fe801 (Metraipolis archive dc_2fed950fe801, sha256 1ebb5d6ccb855ab6860013eec9d0f92fc34a119dcfc44dd0bcd0682ce5946c17)

BibTeX

@misc{dc2fed950fe801,
  title = {Evaluating the Beneficial Effect of Empagliflozin in Reducing Hospitalisation for Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review — Europe PMC PMID:41235287},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41235287},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2fed950fe801; sha256 1ebb5d6ccb855ab6860013eec9d0f92fc34a119dcfc44dd0bcd0682ce5946c17},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41235287. Agents can read the archived copy with the MCP tool read_document.